Jazz Pharmaceuticals plc (JAZZ)
Jazz Pharmaceuticals (JAZZ) is a Top-Ranked Growth Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
International Markets and Jazz (JAZZ): A Deep Dive for Investors
Explore Jazz's (JAZZ) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Jazz Pharmaceuticals: Decent 2025 Outlook, Extended Timeline For Zanidatamab
Jazz Pharmaceuticals ended 2024 on a strong note, beating analyst estimates, and the 2025 revenue outlook is slightly below consensus. The delay in zanidatamab's phase 3 trial results is slightly disappointing but could indicate a better-than-expected treatment effect. I continue to see Jazz as a valuation re-rating candidate, driven by zanidatamab and Zepzelca, return to growth and reduced perceptions of the risks for the oxybate franchise.
Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Jazz Stock Gains as Q4 Earnings & Sales Surpass Expectations
Jazz reports better-than-expected fourth-quarter results. Its newly issued EPS guidance of $22.50-$24.00 for full-year 2025 surpasses our expectations.
Compared to Estimates, Jazz (JAZZ) Q4 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Jazz (JAZZ) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Jazz Pharmaceuticals (JAZZ) Tops Q4 Earnings and Revenue Estimates
Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $6.60 per share, beating the Zacks Consensus Estimate of $5.79 per share. This compares to earnings of $5.02 per share a year ago.
Jazz (JAZZ) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Get a deeper insight into the potential performance of Jazz (JAZZ) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Jazz (JAZZ) Surges 5.2%: Is This an Indication of Further Gains?
Jazz (JAZZ) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Why Jazz (JAZZ) is Poised to Beat Earnings Estimates Again
Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Jazz Pharmaceuticals: Should Sing A Better Tune In 2025
Jazz Pharmaceuticals' stock moved nicely higher post-3Q24 report and FDA approval of zanidatamab, despite challenges in its narcolepsy franchise from Avadel's Lumryz. Jazz's neuroscience franchise faces declining Xyrem sales but sees growth in Xywav and Epidiolex. Oncology growth is driven by zanidatamab's approval and other key drugs like Rylaze and Zepzelca, crucial for achieving Vision 2025 sales goals.
Wall Street Analysts Think Jazz (JAZZ) Could Surge 44.37%: Read This Before Placing a Bet
The consensus price target hints at a 44.4% upside potential for Jazz (JAZZ). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
